High-Dose CBD Significantly Reduced Neuropathic Pain in Spinal Cord Injury: What a New RCT Reveals
| Audience | Patients with chronic neuropathic pain, clinicians managing SCI-related pain, researchers following cannabinoid therapeutics evidence. |
| Primary Topic | High-dose oral CBD in a randomized crossover trial for chronic neuropathic pain in spinal cord injury, published in EClinicalMedicine (Lancet group), May 2026. |
| Source | Read the full study |
High-Dose CBD Significantly Reduced Neuropathic Pain in Spinal Cord Injury: What a New RCT Reveals
Neuropathic pain after spinal cord injury is notoriously treatment-resistant, with roughly half of patients finding no meaningful relief from available medicines. A new placebo-controlled RCT from the University of Sydney tested whether very high doses of CBD — up to 800 mg daily — could change that picture. The results, while modest in magnitude, are statistically significant and represent one of the most rigorous tests of high-dose CBD for chronic nerve pain to date.
| Study Type | Randomized, double-blinded, placebo-controlled, crossover clinical trial |
| Population | Adults with spinal cord injury and chronic neuropathic pain (≥3 months duration); n=40 randomized, 38 in primary analysis; 84% male |
| Intervention | Oral CBD tablets titrated from 200 mg/day to 800 mg/day over 2 weeks, then 800 mg/day for 4 additional weeks (6-week period total) |
| Comparator | Matched placebo tablet (identical in appearance, taste, and smell) |
| Primary Outcome | Change in self-reported pain intensity on a Visual Analogue Scale (0 = no pain; 10 = worst pain imaginable) |
| Sample Size | 40 randomized; 38 included in modified intention-to-treat analysis |
| Treatment Schedule | Two 6-week treatment periods separated by a 4-week washout; crossover design |
| Journal | EClinicalMedicine (Lancet group) |
| Year | 2026 |
| DOI | 10.1016/j.eclinm.2026.103986 |
| Funding / Conflicts | Spinal Cord Injury Research Grant, NSW Health; Lambert Initiative for Cannabinoid Therapeutics, University of Sydney. Authors are affiliated with academic institutions; no industry sponsorship disclosed. |
Robertson and colleagues enrolled 40 adults with spinal cord injury and chronic neuropathic pain lasting at least three months at Neuroscience Research Australia. Participants were randomized to one of two treatment orders in this crossover design — either CBD first then placebo, or placebo first then CBD. Randomization was handled by an unblinded investigator with no participant contact; participants and all other investigators were blinded.
Each treatment period lasted six weeks, separated by a four-week washout to minimize carryover effects. The CBD dose escalated from 200 mg/day at week one up to 800 mg/day by week two, where it remained for the final four weeks. Participants recorded pain scores on a 0-to-10 Visual Analogue Scale three times per day on alternate weekdays throughout the trial.
The primary analysis found a statistically significant treatment-by-phase interaction (p<0.001). During the active treatment phase, mean pain intensity was 3.82 (±0.23) on CBD compared to a mean difference of -0.54 (SE=0.15, p<0.001, 95% CI -0.88 to -0.21) relative to placebo. This translates to approximately 14% pain reduction with CBD versus approximately 6.5% with placebo. Critically, the two treatments did not differ during the inactive (pre-treatment) phase (mean difference <0.01, p=1.00), which validates the crossover design.
Looking at clinical responders — those who achieved at least a 30% reduction in pain — 37.8% of participants met this threshold during CBD treatment versus 11.1% during placebo. This responder analysis provides a more clinically interpretable view of the effect than the group-mean difference alone.
Adverse events were reported by 68.4% of participants during CBD treatment (67 total events) compared to 52.6% during placebo (51 events). The study describes nearly all adverse events as minor. No serious adverse events were directly attributed to CBD. The authors note that participants were taking a range of concomitant medications, and the possibility that CBD interacted with these drugs — potentially affecting both efficacy and adverse event rates — cannot be excluded from the current data.
The higher adverse event reporting rate with CBD relative to placebo (68.4% vs 52.6%) is a signal worth noting, even though individual events were largely mild. Future trials designed to capture adverse event severity ratings and drug interaction data more systematically will be important for characterizing the risk-benefit profile at this dose range.
One of the most consequential methodological findings in this trial was that 78% of participants receiving placebo correctly identified their treatment assignment. This rate substantially exceeds chance (50%), suggesting meaningful unblinding in the placebo group. For a trial measuring a subjective outcome like self-reported pain intensity, unblinding in the control arm raises the possibility that lower expectations among placebo-guessers dampened their reported pain relief — artificially widening the apparent gap between CBD and placebo.
The authors acknowledge this limitation directly. It does not nullify the findings, but it complicates interpretation. Future studies of cannabidiol for pain management will need to address this challenge thoughtfully — whether through active placebos that better mimic CBD’s minor physiological signals, or through outcome measures less susceptible to expectation effects.
The trial enrolled adults with spinal cord injury specifically, but the researchers emphasize that neuropathic pain mechanisms in SCI share pathophysiology with other sources of neuropathic pain — including diabetic neuropathy, chemotherapy-induced peripheral neuropathy, and central post-stroke pain. The endocannabinoid system’s role in descending pain modulation operates across these conditions. While direct extrapolation requires caution, the mechanistic rationale for CBD’s potential benefit is not unique to the SCI population.
The sample was 84% male (n=6 female out of 38 analyzed), which mirrors the demographic reality of spinal cord injury but limits conclusions about how CBD affects neuropathic pain in women. Hormonal factors, body composition differences, and ECS receptor density variations between sexes are clinically meaningful and should inform future trial design.
Chronic neuropathic pain after spinal cord injury is one of the most difficult-to-treat pain conditions in clinical medicine. Gabapentinoids, tricyclic antidepressants, SNRIs, and opioids are first- and second-line options, yet approximately half of patients with SCI neuropathic pain report inadequate relief from existing therapies. This therapeutic gap has driven substantial interest in cannabinoid-based treatments. Prior trials, however, mostly used CBD doses below 300 mg/day and often blended CBD with THC in ways that made it impossible to isolate CBD’s contribution. The Robertson trial is notable precisely because it tested very high-dose pure CBD in isolation — an important step in understanding the compound’s independent analgesic potential.
The endocannabinoid system plays a direct modulatory role in spinal pain circuitry. CB1 and CB2 receptors are expressed in the dorsal horn, and both anandamide and 2-AG have known roles in descending inhibitory control. CBD does not bind CB1 receptors with high affinity; its analgesic mechanism likely involves TRPV1 modulation, inhibition of endocannabinoid reuptake, and possibly anti-inflammatory pathways at the dorsal horn level. Understanding why some patients respond and others do not — and whether ECS tone, receptor density, or genetic variation in cannabinoid metabolism predicts response — is the central unanswered question that should drive the next generation of trials.
Neuropathic pain is one of the most common reasons patients come to our clinic seeking alternatives to conventional treatment — and one of the conditions where the existing pharmacological toolkit falls shortest. This trial is meaningful to me not because it offers a clinical roadmap, but because it demonstrates that very high-dose CBD in a rigorous trial design produces a statistically significant, directionally consistent reduction in pain. The 37.8% responder rate at ≥30% reduction is not a cure, but for a population where half of patients get no meaningful relief from anything currently available, it matters.
What I find clinically useful here is the dose. Most of what I see in practice involves products delivering 20 to 50 mg of CBD daily. This trial used 800 mg/day — nearly an order of magnitude higher than typical consumer doses and even many medical doses. That is not a signal to push patients toward high doses without oversight; it is a signal that dosing in cannabinoid medicine is still not calibrated by evidence, and that what we consider ‘high-dose’ in clinical practice may still be pharmacologically insufficient for conditions like central neuropathic pain. That conversation with patients deserves more rigor and more honesty than it currently gets.
Reading a Crossover Trial: What the Numbers Mean and Where They Stop
Crossover trials have a specific structure that changes how results should be interpreted. Unlike a parallel-group RCT where two separate groups receive two different treatments, a crossover trial gives each participant both treatments in sequence, with a washout period between. This means each participant serves as their own control, reducing variability from individual differences. That is a genuine strength — and it makes the comparison more statistically efficient with a smaller sample.
But crossover designs also have specific vulnerabilities. Carryover effects — where the first treatment influences the second — can confound results even with a washout period. Sequence effects, where the experience of one phase shapes how participants rate the next, are also possible. The Robertson trial included a validity check for carryover (the inactive-phase comparison showed no difference), which is a real methodological strength. Still, the subjective nature of the primary outcome and the documented unblinding in the placebo group introduce uncertainty that can’t be eliminated statistically.
How to read the primary result
Step 1: Understand what was measured
Pain was measured on a Visual Analogue Scale from 0 (no pain) to 10 (worst pain imaginable), recorded three times a day on alternate weekdays. This is a validated and widely used clinical tool, but it is entirely self-reported and therefore susceptible to expectation effects.
Step 2: Interpret the mean difference
The mean difference between CBD and placebo was -0.54 points on the 0-10 VAS (95% CI -0.88 to -0.21). This is statistically significant (p<0.001) but modest in absolute terms. A clinical rule of thumb is that a 1-2 point change on a 10-point VAS is considered clinically meaningful for chronic pain. At -0.54, this trial sits below that threshold on the group-mean level, though the responder analysis (37.8% vs 11.1% achieving ≥30% reduction) suggests a meaningful benefit in a subgroup.
Step 3: Weigh the blinding problem
Seventy-eight percent of placebo participants correctly guessed their treatment. This is a critical number. If placebo participants had lower expectations because they suspected they were on placebo, their reported pain relief may have been suppressed — artificially enlarging the apparent CBD-placebo gap. The effect may be real, but its precise magnitude is uncertain because of this.
Step 4: Distinguish group means from individual responses
The group mean conceals heterogeneity. Thirty-seven percent of people had a strong response; about 62% did not. In clinical practice, identifying which patients are likely to respond before committing to an 800 mg/day course would be practically important and is currently unknown from this trial.
The Same Study Can Mean Different Things Depending on the Question Being Asked
Scientific papers rarely answer a single question. Patients, clinicians, researchers, and critics can read the same data differently. These evidence-based lenses show where this trial is useful, where it remains uncertain, and how easily it can be overstated.
What This Might Mean If You Live with Neuropathic Pain
If you are someone living with chronic nerve pain after a spinal cord injury, this trial offers a carefully qualified reason for cautious hope. In a study where participants tried both CBD and a placebo, significantly more people on CBD reported a meaningful reduction in pain intensity — roughly 38% achieved at least a 30% improvement on CBD, compared to about 11% on placebo. That is a real difference, and for a condition where roughly half of patients find no relief from standard treatments, it is worth noticing.
At the same time, the average pain reduction was modest. The trial used doses far higher than most commercially available CBD products — 800 mg per day — and even at that dose, most participants (about 62%) did not reach the ≥30% response threshold on CBD. The study enrolled only 40 people, almost all of them men, and only followed participants for six weeks.
The core takeaway is this: CBD at high doses appears to do something real for nerve pain in some people, but it does not work reliably for everyone, and this trial is not large enough to tell you in advance whether you are likely to be a responder. Any decision about trying CBD for neuropathic pain belongs in a conversation with your physician, where your specific medications, other health conditions, and individual history can all be considered.
Exam-Room Relevance: What to Say and What to Hold Back
For clinicians managing neuropathic pain in patients with spinal cord injury — or neuropathic pain more broadly — this trial advances the evidence base without yet changing the standard of care. It is the largest and most rigorous high-dose CBD trial to date for this indication. The fact that it used a prospectively registered crossover design, demonstrated crossover validity via the inactive-phase null comparison, and achieved statistical significance on the primary VAS endpoint gives it more clinical credibility than most prior CBD pain studies.
The practical challenge is patient selection. The responder rate of 37.8% vs 11.1% on placebo is compelling, but the trial provides no predictors of response. Without knowing which patients are likely to benefit, clinicians face a ‘try and see’ approach. Given that most patients with SCI neuropathic pain are already on gabapentinoids or other medications with meaningful side-effect and interaction profiles, adding 800 mg/day of CBD to an existing regimen requires careful consideration of CBD’s inhibition of CYP450 enzymes — an issue the trial acknowledges but does not quantify.
The unblinding problem (78% of placebo participants correctly guessed their treatment) should be disclosed to patients asking about this study. It does not invalidate the trial, but it means the effect size may be partly inflated by expectation bias. Discussing this honestly supports shared decision-making without dismissing the finding.
Where Reasonable Doubt Lives in This Trial
The most durable source of skepticism in this trial is not the statistics — the p-values are clean, and the crossover validity check passed. The real problem is that 78% of placebo participants correctly identified their treatment, which is vastly above chance. In a trial measuring self-reported pain on a subjective scale, correct treatment identification in the control arm creates a plausible mechanism for inflating the apparent benefit of the active treatment: if you know you are probably on placebo, your expectation of less benefit may reduce your reported improvement.
The small sample size compounds this concern. With only 40 participants, the trial lacks the statistical power to detect interactions or moderators, and a single influential outlier can shift group means meaningfully. The trial reports modified intention-to-treat results, which is the right approach, but n=38 in the primary analysis remains very small for a chronic pain intervention trial in a heterogeneous condition like SCI neuropathic pain.
A skeptic would also note the predominantly male sample (84%), the single Australian center, and the absence of any objective pain biomarkers. The trial gives us a statistically significant reduction in a self-reported outcome in a small, unrepresentative sample with a known blinding failure. That is worth studying further; it is not worth overinterpreting now.
Where the Design and Inference Start to Separate
The primary effect size (mean difference = -0.54 on a 0-10 VAS, 95% CI -0.88 to -0.21) is statistically significant with a reasonably tight confidence interval. But a clinically meaningful change on a 10-point VAS for chronic pain is generally considered to be in the 1.0 to 2.0 point range. The lower bound of the confidence interval is -0.88 — still below 1.0. The trial does not establish that the effect exceeds a clinically meaningful threshold at the group level. The responder analysis (37.8% vs 11.1% at ≥30% reduction) is more compelling clinically, but responder analyses in crossover trials carry additional methodological complexity and should be interpreted cautiously.
The crossover design, while efficient, assumes that pain levels at the start of each treatment period are comparable. The trial validated this with the inactive-phase comparison (mean difference <0.01, p=1.00), which is genuinely reassuring. However, the four-week washout may be insufficient to clear psychological carryover effects — especially expectation and learning effects in a population that is actively rating pain multiple times per day throughout the trial.
Finally, the adverse event analysis describes frequency but not severity or duration in granular terms. Sixty-eight percent of CBD participants reporting adverse events is not trivial, even if events were mostly mild. Without structured severity ratings and a systematic CBD-drug interaction assessment, the tolerability conclusion is incomplete.
Where This Trial Fits in the Neuropathic Pain and CBD Literature
Prior systematic reviews and Cochrane analyses of cannabinoids for neuropathic pain — including those covering both THC-dominant and CBD-dominant products — have generally found limited and inconsistent evidence of benefit, with methodological heterogeneity across trials making pooled conclusions difficult. A key methodological criticism of earlier trials was the use of doses far below what might be pharmacologically active for central neuropathic pain. Most prior CBD trials used doses of 150 to 300 mg/day at most.
The Robertson trial addresses the dosing gap directly by testing 800 mg/day — a dose range consistent with what the Lambert Initiative and other Australian research groups have used in epilepsy and other neurological conditions. To the extent that prior negative or null CBD trials were underdosed, this trial begins to test whether dose matters. The answer, at least for this population, appears to be yes — though the finding needs replication.
Based on the supplied source alone and general familiarity with the CBD pain literature, this comparison should be read cautiously, as the specific prior studies used for direct dose-response comparison have not been independently reviewed for this Lens Card. The broad claim — that this is a higher-dose and more rigorously designed trial than most prior CBD pain RCTs — is consistent with what the paper itself asserts and with the general published record in the field.
If the Finding Is Partly Right, What Does It Mean Practically?
Eight hundred milligrams of CBD per day is a substantial dose that bears no resemblance to what most CBD products deliver in practice. Consumer CBD products typically provide 10 to 30 mg per serving. Even medical CBD formulations commonly used for conditions other than epilepsy tend to be prescribed in the 50 to 200 mg/day range. If the clinical benefit observed in this trial is real and dose-dependent, it raises an immediate practical question: how would such a regimen be delivered, titrated, and monitored in clinical practice?
The titration schedule in this trial (200 mg → 800 mg over two weeks) required pharmaceutical-grade tablets with a matched placebo — not a realistic description of what is currently available in most cannabis medicine practices or dispensaries. Product variability, labeling accuracy, and bioavailability differences between CBD formulations could substantially affect outcomes in a real-world setting.
Drug interactions are a practical concern at this dose. CBD is a known inhibitor of CYP2C19 and CYP3A4 enzymes, and many patients with SCI are on medications cleared by these pathways — including gabapentinoids, muscle relaxants, antidepressants, and anticoagulants. Any clinical consideration of high-dose CBD in this population requires a medication review.
What the Next Honest Study Would Need to Show
The most immediate need is replication in a larger, more diverse sample. A trial with 200 to 400 participants, balanced by sex, including patients with neuropathic pain from multiple etiologies (not just SCI), and with a longer follow-up period (six months minimum) would substantially strengthen or refine the current finding. If the effect is real and dose-dependent, a dose-ranging trial comparing 200, 400, 600, and 800 mg/day would clarify the dose-response relationship and potentially identify a minimum effective dose.
The blinding problem is solvable. Active placebos that produce minor physiological sensations similar to CBD (such as low-dose compounds that produce mild sedation or slight changes in affect without analgesic effect) could be used in future trials to reduce the rate of correct treatment guessing. Alternatively, objective endpoints such as quantitative sensory testing, pain biomarkers, or functional neuroimaging could supplement or partially replace self-reported VAS scores.
A practically important question this trial cannot answer is who responds. A prospective biomarker study — incorporating ECS tone measurements (circulating AEA, 2-AG), pharmacogenomic profiling of CYP450 and cannabinoid receptor variants, and baseline neuroimaging of descending pain modulation — could identify predictors of CBD response in neuropathic pain. That kind of precision medicine framing is where the field needs to go.
How This Trial Is Likely to Be Distorted
The most predictable distortion is the headline form: ‘CBD Cures Nerve Pain.’ This is a distortion. The trial showed a statistically significant but modest average pain reduction in 40 people over six weeks. About 62% of participants did not achieve a ≥30% response on CBD. The finding is not a cure, does not generalize to all neuropathic pain conditions, and was not observed across a clinically diverse or large population.
A second common misread will be dosing extrapolation: ‘This proves you should take 800 mg of CBD every day.’ This is also a distortion. The trial used pharmaceutical-grade oral tablets under medical supervision with a controlled titration schedule. Consumer CBD products vary widely in actual CBD content, bioavailability, and purity. Translating an 800 mg/day finding from a controlled RCT into a consumer supplement recommendation is not scientifically supportable.
On the other side of distortion, prohibitionist framings may overweight the adverse event rate (68.4% of CBD participants reported AEs) without noting that 52.6% of the placebo group also reported AEs, that nearly all events were minor, and that the authors found no serious adverse events attributable to CBD. Citing only the CBD adverse event rate without the placebo comparator is misleading in the opposite direction.
A final nuanced misread: treating the 37.8% responder rate as evidence that ‘CBD works for most SCI patients’ — when in fact the majority did not respond. The correct framing is: a meaningful minority of patients appears to benefit substantially, which is clinically useful information but different from a broadly effective treatment.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan
Want to discuss this topic with other patients and caregivers? Join the forum discussion
Frequently Asked Questions
What dose of CBD was used in this neuropathic pain trial?
The trial escalated the dose from 200 mg per day in the first week up to 800 mg per day by the end of week two, where it remained for the final four weeks of each six-week treatment period. This is substantially higher than most clinical and consumer CBD use, which typically ranges from 20 to 200 mg daily.
How much pain relief did CBD actually provide?
On average, participants reported a mean pain reduction of approximately 14% with CBD compared to approximately 6.5% with placebo. The mean difference between treatments was -0.54 on a 0-to-10 Visual Analogue Scale (95% CI -0.88 to -0.21, p<0.001). About 37.8% of participants achieved a ≥30% reduction in pain on CBD versus 11.1% on placebo.
Was high-dose CBD safe in this trial?
The study reports that CBD was generally well tolerated at 800 mg/day. Adverse events were reported by 68.4% of CBD participants (67 total events), but also by 52.6% of placebo participants (51 events). The authors describe nearly all adverse events as minor. No serious adverse events directly attributable to CBD were observed. However, the trial was not designed to capture long-term safety, and participants were on various other medications that may have interacted with CBD.
Who were the participants in this trial?
The trial enrolled 40 adults aged 18 or over with spinal cord injury and chronic neuropathic pain lasting at least three months. Of the 38 participants included in the primary analysis, 84% were male (approximately n=32) and 16% (n=6) were female. The trial was conducted at Neuroscience Research Australia.
Can these results apply to neuropathic pain from causes other than spinal cord injury?
The researchers explicitly note that the findings may be relevant to people with chronic neuropathic pain from other causes, because the underlying mechanisms of neuropathic pain share pathophysiology across etiologies. However, this is a hypothesis rather than a proven generalization — the trial enrolled only SCI patients, and direct evidence in other neuropathic pain populations at this CBD dose is lacking.
What is the Lambert Initiative for Cannabinoid Therapeutics?
The Lambert Initiative is a research program based at the University of Sydney, funded by a philanthropic gift from Barry and Joy Lambert. It conducts rigorous, academic clinical and preclinical research into cannabinoid medicines, with particular focus on pain, epilepsy, and neurological conditions. It is widely regarded as one of the most credible and independent cannabinoid research programs globally.
Why did so many placebo participants correctly guess their treatment?
Seventy-eight percent of participants receiving placebo correctly identified that they were on placebo — far above the 50% that would be expected by chance. The study does not explain the precise mechanism, but likely contributors include the absence of any of CBD's subtle physiological effects (such as mild sedation or slight changes in affect) that participants may have noticed during the CBD phase. This kind of unblinding is a recognized challenge in cannabis medicine trials.
How does CBD reduce neuropathic pain — what is the mechanism?
CBD does not bind with high affinity to CB1 or CB2 receptors the way THC does. Its proposed mechanisms for analgesia include TRPV1 receptor modulation (a channel involved in pain signaling), inhibition of anandamide reuptake (which increases endogenous cannabinoid activity), anti-inflammatory effects at the dorsal horn of the spinal cord, and possible modulation of descending pain inhibitory pathways. The precise mechanism responsible for the reduction observed in this trial is not established.
Can I take 800 mg of CBD per day for my nerve pain?
This is a question that requires a direct conversation with your physician. The 800 mg/day dose in this trial was administered as pharmaceutical-grade tablets under medical supervision, with a controlled titration protocol, in participants whose medications were monitored throughout. Consumer CBD products vary enormously in actual CBD content and bioavailability, and CBD at high doses can interact with medications processed by CYP450 liver enzymes — including many common drugs. Do not attempt to replicate this dose using over-the-counter products without medical oversight.
What should happen next in the research?
The researchers and independent commentators identify the same priorities: replication in a larger, more diverse sample that includes more women and participants with neuropathic pain from causes other than SCI; a longer follow-up period to assess durability; a dose-ranging study to identify the minimum effective dose; and development of strategies to address blinding challenges in future trials. Biomarker research to identify which patients are most likely to respond would also be clinically valuable.
